#United States #New York #Class Action #Gross Law Firm #Soleno Therapeutics

Soleno Therapeutics Investors Alert: Class Action Lawsuit Pending

The Gross Law Firm is drawing attention to a significant upcoming deadline for shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). A class action lawsuit is currently underway, and potential plaintiffs must register by May 5, 2026. Investors who acquired shares during the specified class period are particularly encouraged to act quickly.

Key Details of the Class Action Lawsuit

The class action lawsuit is rooted in serious allegations against Soleno Therapeutics regarding its Phase 3 clinical trial program for its product, diazoxide choline extended-release tablets (DCCR). During the class period, which spans from March 26, 2025, to November 4, 2025, it is claimed that the company issued materially false or misleading statements while failing to disclose critical safety concerns linked to DCCR. Key allegations include:

• - Systematic downplaying and misrepresentation of evidence related to safety issues, particularly concerning excess fluid retention among clinical trial participants.
• - Significant risks associated with administering DCCR for treating hyperphagia in individuals with Prader-Willi Syndrome (PWS) that may not have been adequately disclosed.
• - Implications that these risks may lead to lower commercial viability coupled with undisclosed dangers tied to adverse events post-launch, including potential repercussions like prescriber reluctance and adverse regulatory actions.

This class action could have substantial implications for investors as it highlights the precarious nature of investing in companies that may overlook essential safety disclosures.

Importance of Registration

Shareholders who believe they qualify should not delay in registering for this class action. Registration provides investors with added benefits, such as enrollment in a portfolio monitoring system, which ensures they receive ongoing updates throughout the lifecycle of the case.

To register, interested parties must visit the following link: Registration Link.

Next Steps for Affected Shareholders

Upon registration, shareholders will be kept informed and are encouraged to consider seeking lead plaintiff status, although it is important to note that this is not a requirement for participation in the lawsuit. The deadline for seeking lead plaintiff status is also May 5, 2026. There is no financial cost or obligation involved in participating in this lawsuit.

About The Gross Law Firm

The Gross Law Firm is a well-known class action law firm that focuses on protecting investor rights affected by corporate malfeasance. Their mission revolves around advocating for investors who may have suffered financial losses due to fraud or misleading corporate practices. The firm emphasizes the importance of corporate accountability and has a track record of pursuing recovery for affected investors when securities are artificially inflated by wrongful acts.

For more information regarding the lawsuit or to discuss your potential claims, shareholders are encouraged to contact The Gross Law Firm directly:
Contact Information:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In conclusion, the Gross Law Firm's announcement serves as a crucial reminder for shareholders of Soleno Therapeutics, Inc. to take immediate actions regarding the pending class action lawsuit. Engaging in this process could potentially lead to recovery of losses incurred during the class period due to the company’s alleged breach of duty in providing investors with accurate and truthful information.

Stay vigilant and ensure your voice is heard during this legal proceeding.